Plain-English translation of NCT06854445 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether TQB2825, a new antibody medication, works better when combined with two chemotherapy drugs (gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or stopped responding to earlier treatment. Researchers want to see if adding this medication to chemotherapy can help more patients achieve remission. About 55 people will participate in this study.
Diffuse large B-cell lymphoma is an aggressive cancer that sometimes comes back after initial treatment or doesn't respond well to it. Doctors are looking for better treatment options for these patients, and this medication has shown promise in early testing.
You likely qualify if…
You likely don't qualify if…
You would receive TQB2825 injections along with chemotherapy infusions (gemcitabine and oxaliplatin) on a treatment schedule determined by the research team. You'll have regular visits for blood tests, scans, and check-ups to monitor how the treatment is working and any side effects. The exact length of treatment will depend on how you respond and how well you tolerate the medications.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China